Nuvilex (NASDAQ:PMCB – Get Free Report) is expected to be posting its resultson Wednesday, July 1st. Analysts expect Nuvilex to announce earnings of ($0.06) per share for the quarter.
Nuvilex Trading Up 1.1%
PMCB opened at $0.78 on Wednesday. The stock has a 50-day moving average price of $0.76 and a 200-day moving average price of $0.78. Nuvilex has a 12-month low of $0.63 and a 12-month high of $1.51. The stock has a market capitalization of $8.34 million, a P/E ratio of -0.69 and a beta of 0.51.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Nuvilex Company Profile
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.
Read More
- Five stocks we like better than Nuvilex
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
- Liquid Gold: The AI Cooling Retrofit Trade
- 3 Dividend Stocks Under $30 to Anchor Your Portfolio
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
